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Abstract
Wells, Carlos Montez. PhD. The University of Memphis. May 2021. Acylated
Nanofibrous Chitosan Biomaterials for Prolonged Biofilm Inhibition and Pain Mitigation.
Major Professor: J. Amber Jennings
Microbial contamination and biofilm formation in complex musculoskeletal trauma is an
ongoing clinical challenge. Infection and biofilm formation in these injuries cause significant
pain in addition to physical, socioeconomic, mental, and familial burdens to patients while
increasing strains on the healthcare system. Biofilm-based infections are prevalent and are
particularly difficult to treat due to the biofilm's tolerance to antimicrobials and ability to evade
natural body defenses. Primary strategies to treat biofilm are 1) inhibition, 2) dispersal, and 3)
removal. A promising strategy is to use the biofilm dispersal agent 2-decenoic acid (2DA) and its
analogs combined with antimicrobials to inhibit and treat biofilm-based infections. Also, high
concentrations of local anesthetics (LA) that effectively block pain locally may provide
advantages for preventing and treating biofilm-based infections. Local antimicrobial delivery
systems offer benefits over systemic delivery of therapeutics, but release kinetics, residency
time, and ability to deliver hydrophobic therapeutics, i.e., LA and 2DA, are challenging. Burst
release of antimicrobials is ineffective at eradicating infection and may also contribute to the
growing incidence of antimicrobial tolerance. Surface modifications of chitosan biomaterials
through acylation have demonstrated an ability to improve hydrophobic therapeutics' release
kinetics while supporting wound healing. In these studies, we investigated the combinatorial
antimicrobial effects of 2DA and LA for common pathogenic microorganisms. We further tested
the hypothesis that direct acylation of chitosan with 2DA analogs could inhibit biofilm
formation. We then evaluated the efficacy of acylated chitosan biomaterials in releasing
therapeutics and treating biofilm-based infections in in vitro and in vivo infection models.
vi

Results revealed that combinations of LA ≥ 5 mg mL-1 and 2DA ≥ 250 mg mL-1 have additive or
synergistic activity against microorganisms. We confirmed that chitosan biomaterials could:
1. Be directly acylated with 2DA to resist biofilm formation even without therapeutics
loaded.
2. Extend the release of loaded therapeutics to at least one week after acylation.
3. Reduce infection occurrence in both in vitro and in vivo infection models after acylation
and loading with 2DA and LA.
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1. CHAPTER 1
Introduction
Background
Incidence
Many musculoskeletal procedures and traumatic injuries require bone fixation devices to assist with the
healing process. Estimates predict that open fracture and extremity trauma occur at least six million times per
year in the United States (1). Musculoskeletal injuries requiring fixation devices have infection rates of 5% (2),
which increases to over 50% for complex injuries such as compound fractures (3-5). Damaged tissue and pain
are always consequences of traumatic musculoskeletal wounds that require active treatment efforts. The wounds
can result from traumatic musculoskeletal injuries, medical device implantation, or surgical procedures.
Medical device implantation annually accounts for ~2 million healthcare-associated infections, often requiring
aggressive debridement of surrounding tissue after implant removal causing patient trauma and pain (6, 7).
Infection Rates
The American Academy of Orthopaedic Surgeons (AAOS) estimates that more than 500,000 surgical
site infections (SSIs) occur after an orthopaedic procedure (8). The infection rate that causes total hip
arthroplasty (THA) revisions is 14.8% (9). The increase in bacterial antibiotic resistance in musculoskeletal
infections further complicates the fight against eradicating or inhibiting infections (8). Antibiotic misuse is a
significant contributor to the multi-drug resistant bacterial strains compounded by antibiotic-resistant biofilm,
limiting broad-spectrum practical treatment options in the fight against infections (10, 11). Bacterial
colonization and subsequent biofilm formation can occur during the first 72 hours of a traumatic injury (12, 13),
making wound protection during this time frame critical. Infection-related complications increase
socioeconomic costs for patients (14). Local delivery systems may have advantages in treating musculoskeletal
injuries, such as complex extremity wounds requiring fixation hardware, when used as adjunctive therapy to
9

systemic delivery. Local delivery devices are increasing in demand due to the need to treat and prevent infection
and pain management during wound healing processes. Local antimicrobial delivery, including but not limited
to anti-biofilm fatty acids (FA) and local anesthetics (LA), may be efficacious in treating or preventing infection
and moderating pain while reducing patient trauma and economic costs. The anti-biofilm FAs assist in
inhibiting biofilm formation, which increases infectious bacteria’s susceptibility to natural host defenses and
antimicrobial agents. Besides their primary pain treatment function, LAs can exhibit antimicrobial properties
that can enhance locally delivered antimicrobial agents’ efficacy.
Additionally, when treatment solutions include LAs, pain mitigation may reduce the need for
prescription and systemically delivered opioids. This project’s principal goals include developing and
evaluating local delivery systems for hydrophobic therapeutics such as fatty acids and local anesthetics. The
local delivery systems may extend their elution profiles for infection prevention in wounds or other complex
traumas.
Normal Healing
Physiological impairments resulting from damage to skin, muscle, bone, or other tissue define wounds.
Traumatic injuries, acute wounds, surgical wounds, or accompanying co-morbidities can result in
musculoskeletal wound infections, which further complicate and impair patient healing and recovery (15).
Bacterial colonization occurs with a greater probability in open fractures in comparison with surgically created
wounds due to contamination from the environment (16). Co-morbidities, including diabetes, malnutrition,
chronic steroid use, and peripheral vascular disease, among other chronic illnesses, exacerbate tissue healing
impairments (17), and increase infection risks (18). Musculoskeletal infectious complications may cause
physical, emotional, and monetary stresses to those patients experiencing them (19).
Natural wound healing processes include various cell types responsible for hemostasis, inflammation,
proliferation, and remodeling (20). During the first eight hours, neutrophils migrate from surrounding areas
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removing foreign bodies, bacteria, non-viable tissue, and other debris from the wound site (21). Macrophages
migrate to the wound site 24 - 48 h after injury, with concentrations starting to decline at 72 h or longer
depending on the wound size (19). Neutrophils evacuate the wound site as macrophages and mast cells clear the
area of debris (17). Within hours 48 - 72, or longer depending on wound austerity, epithelial cells construct a
thin epithelial layer over the cleaned and disinfected wound, providing a barrier from the external environment
(16, 22). Tissue remodeling begins, on average, within 4 - 8 weeks of the injury and persists for months to
years, depending on wound severity (21).
Musculoskeletal Injuries
Efficacious wound management can assist innate responses in restoring the wound site. Musculoskeletal
injury treatments that mitigate complications such as pain and infection result in improved patient outcomes and
prognosis (23). Some of the primary principles for managing complex musculoskeletal wounds include
infection prevention, irrigation, debridement, fixation, and closure (24). While there are currently few treatment
standards (25), there is a consensus that early intervention in applying preventative measures results in more
favorable outcomes (14). Debridement removes non-viable tissue and foreign materials from the wound (26);
however, debridement has limited efficacy when surgeons cannot visualize where infecting microorganisms
reside. Non-viable tissue leads to necrotic tissue, which can activate natural inflammatory processes that inhibit
wound healing and promote microbe proliferation (27). In absence of methods to visualize bacteria, a common
practice by surgeons is to debride skin and subcutaneous tissue debridement until capillary bleeding occurs, as
this is a sign of healthy undamaged tissue (28). The magnitude of soft tissue damage and contamination may
require additional debridement, typically occurring after 24 - 48 h (29).
Irrigation or lavage removes smaller foreign bodies by rinsing with an aqueous solution to reduce
bacterial concentrations. Copious amounts of irrigation fluid, approximately 10 L, are discussed in practice;
however, this is not without controversy (30). The risk for infectious complications increases when ballistic or
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explosions occur due to the possibility of bacteria spreading along tissue planes (31). Antimicrobial
administration during irrigation is a potential treatment solution that moderates the risk of patient infection (32).
The presiding surgeon can adjust the antibiotic lavage treatment to counter suspected bacterial contaminants
(33). Recent clinical practice guidelines issued by the World Health Organization (WHO) and the Centers for
Disease Control and Prevention (CDC) recommend the inclusion of aqueous povidone-iodine solutions for the
prevention of SSI (31, 33-36). Some current physician-directed or selected wound irrigation solutions include
povidone-iodine (0.35%), chlorhexidine (0.05%), sodium hypochlorite (0.125%) and solutions containing two
or more antimicrobials (37). Fixation and closure inhibit additional bone and soft tissue damage and provide a
nidus for bacterial attachment and biofilm formation (38). Intramedullary nails, screws, and plates are a few
current methods used to stabilize fractures; future improvements are possible for every modus (39).
Intramedullary nail implementation to treat lower-extremity fractures may disrupt bone circulation (34, 35).
Precision in fracture bone alignment usually requires the use of plates and screws (39, 40).
Additionally, transarticular or upper-extremity fracture treatments often require screws and plates (14,
41). More severe wounds involving crushed or pulverized bone and surrounding soft tissue damage may require
titanium or stainless steel alloy rods, plates, wires, and screws (1, 42). Total hip and knee arthroplasties
necessitate fixation and stabilization for adequate bone repair (41). Wound closure stipulations dictate if
available soft tissue or local or free muscle flaps may assist in soft tissue reconstruction (41). In the most
extreme cases, non-abated infection or nonrepairable damage may force the surgeon to amputate the affected
extremity (43).
Currently, prevention is the most successful infection treatment; however, microorganisms at a rate of
up to 65% reportedly contaminate severe, open musculoskeletal wounds (44). In the absence of instrumentation
implanted during surgical procedures, infection rates are a much lower 5%, demonstrating the role these
implants play in biofilm-associated infection (44, 45). Preexisting co-morbidities increase the probability of
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infection onset (44). Infection symptoms may include chills, headaches, fever, and stiffness, pain, erythema, and
wound drainage (46). Infection diagnostic tools include blood tests, imaging, polymerase chain reaction (PCR),
and microbiological cultures (43-45). Administering systemic antibacterial therapy is typically recommended,
especially if the patient cannot undergo additional surgical procedures (47). Systemically delivered
concentration levels at the wound site generally are below biofilm inhibiting levels, which can be up to 1,000
times greater than inhibitory concentrations for planktonic bacteria. Biofilm-inhibiting antibiotic levels
delivered to a wound site systemically would cause harmful side effects to the ear, kidneys, or other organ
systems (48, 49).
Financial Burden
Potential long-term wound infection effects include reducing the quality of life, prolonged systemic
antibiotic therapy, delayed wound healing, latent infection recurrence, loss of limb, and revision surgeries (50).
These outcomes can significantly increase medical costs (44), with SSIs in the USA accounting for
approximately a $1.6 billion annual healthcare cost inflation (51). SSI attributable costs can average between
$10,000 – 30,000 per occurrence (52-54). SSIs have the most significant annual costs comparing to all other
infection sites (51). SSIs cost between $3.2 - 8.6 billion using the consumer price index for all urban consumers
(CPI-U) and $3.5 - 10 billion using the consumer price index (CPI) for hospital inpatient services, according to
a CDC report (51). The U.S. Bureau of Labor Statistics constructs the CPI-U which measures the average
change over time in prices paid by all urban consumers for goods and services purchased for day-to-day living
(51). Several additional variables can result in the most undesired outcomes, i.e., treatment failure or patient
death (2, 41)
Infection/Biofilm Formation
The most common microorganisms that lead to pathogenic infections are Staphylococcus aureus
(S. aureus), Staphylococcus epidermis (S. epi), Pseudomonas aeruginosa (P. aeruginosa), and
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Acinetobacter baumannii (A. baumannii) (55). These bacteria, often isolated from gastrointestinal (GI) tracts
and skin of healthy individuals’ flora, may become pathogenic when introduced to wound sites (56). S. aureus,
which is the culprit in up to 50% of all infections, including arthritis, myositis, osteomyelitis, and implanted
devices (46, 55), is a prominent contributor to prosthetic joint infections (57, 58) and a leading cause of
nongonococcal bacterial arthritis (2). These problems are exacerbated as resistance by S. aureus to antibiotics,
first discovered in the ’90s, is increasing at alarming rates (55). S. aureus’ resistance nullifies many
beta-lactam antibiotics’ efficacy, including methicillin-based specific-antibiotics, which work by inhibiting
peptidoglycan cell wall synthesis in Gram-positive bacteria peptidoglycan cell wall synthesis (59). As bacteria
resistance propagates, vancomycin-resistant S. aureus (VRSA) has become an increasingly problematic issue
(60, 61), becoming a major nosocomial pathogen in the USA (60).
Gram-positive and Gram-negative specific broad-spectrum are antimicrobial agents typically
administered to open fracture wounds to prevent infections. Bacteria adhering to wound tissue, on surfaces of
implanted biomaterials, or to both may form a biofilm, which consists of a community of attached bacteria that
can secrete ions, nutrients, polysaccharides, and other survival-promoting exopolymeric secretions (62).
Persister cells within biofilm have lowered metabolic activity, making them less susceptible to antibiotics that
work by interfering with growth or division. The low metabolic activity of the persister cells requires higher
doses and concentrations of antibiotics to eradicate biofilm.
When the injury involves open fractures, infections develop at a 50% rate (8, 41). Due to open fractures’
exposure to the environment, local antimicrobial agents combined with simple debridement and irrigation
procedures are ineffective at infection prevention in complex injuries involving open fractures (8, 41). Infection
prevention solutions are considered advantageous for novel research because of the increasing number of
orthopaedic implant procedures with an infection rate of 5% (14, 42). Biofilm, surface adhering bacteria,
present costly and exceptionally difficult-to-overcome ongoing challenges to infection management (63).
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Biofilm formation begins as a single planktonic bacterium attaches to a surface, e.g., an implanted device or
wound bed (Figure 1.1). Bacteria within the biofilm directly communicate with each other through secretion
and recognition of small molecules such as diffusible signaling factors (64). Biofilm can readily form on
implanted devices due to the biomaterial’s surfaces through passive adsorption, presenting additional treatment
challenges (65). Implanted devices passively adsorb bacteria on their biomaterial-based surfaces after
implantation procedures. Post-surgical infection risk may increase in the presence of implanted biomaterials due
to the host defense weakness exploitation by established biofilm bacteria (65). Microbial colonization of
surfaces, known as biofilm formation, can cause damage to adjacent tissue damage and spread to cause
pathogenic biomaterial-centered sepsis (66). Microbial colonization has implications as a primary causative
pathogenesis factor in implant failures (44, 45). Additional surgeries for implant removal and replacement are
often the only solution to eradicate implant-associated biofilm infections due to current treatment options’
effectiveness (8, 67). Gram-positive aerobes, largely staphylococci, are responsible for a vast majority of
implant device-associated orthopaedic infections (68).
Antimicrobial vulnerability and tolerance of biofilm can contribute to challenges in preventing and
treating biofilm-associated infections (69). Conventional methods demonstrate limited success in preventing
and treating biofilm-associated infections partly due to the evolution of biofilm antimicrobial tolerance.
Antibiotics that possess high activity levels against various planktonic bacteria have demonstrated minimal to
no success when evaluated against biofilm at the same concentration level; however, high activity antibiotics
can be efficacious against biofilm at increased concentrations. Antimicrobials may penetrate the exopolymeric
substance formed by bacteria; however, dormant persister cells may inhibit antibiotics from penetrating the cell
membrane (70). Due to persister cells’ nature and presence, a principal antibiotic mechanism targeting
metabolically active or dividing cells becomes less effective, often requiring 1000x concentrations than
efficacious planktonic concentrations (71). Some studies indicate that combining antimicrobials may increase
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efficacy against biofilm with some antibiotics allowing bacteria recurrence when used alone (72).
Implant-associated biofilm infection that requires removal directly impacts patient comfort, quality of life and
increases the risk for surgical complications (64, 65). Novel treatment options’ development and
implementation are needed to reduce implant-associated biofilm infection removal surgeries.

Figure 1.1. Biofilm formation and dispersion cycle pictorial depiction (reproduced with
permission from © Springer Nature Singapore Pte Ltd. 2019)

Three aspects: visual assessment, definitive treatment goals, and treatment confirmation inform the
antibiotic selection process for musculoskeletal wound infection treatment (73). These aspects include injury
location, presenting symptoms, and common nosocomial pathogens, if present. Early antimicrobial
administration increases infection prevention effectiveness and moderates the wound’s exposure to the
surrounding environment (74). A pathogen’s susceptibility to antibiotics is a limiting factor when selecting
antibiotics for infection treatment. Other constraints include maintaining an antibiotic concentration at the
infection site above the minimal inhibitory concentration (MIC) level for a period long enough to ensure
eradication of all microorganism contaminants. Antimicrobial tolerance increases the difficulty of combating
musculoskeletal wound infections (63). Recent advances in wound screening allow identifying certain microbes
before treatment (67, 75).
Fatty acids have shown an ability to disperse biofilms in many strains of microorganisms, with
cis-2-decenoic acid (C2DA) showing particular activity against multiple strains of bacteria (68). Bacteria such
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as P. aeruginosa produce C2DA, a medium-chain fatty acid chemical messenger (Figure 1.2) that signals
biofilm dispersion for numerous bacterial strains (68). Davies et al. report that C2DA can disperse biofilm (76),
and Jennings et al. demonstrated that it has inhibitory effects against S. aureus biofilm (62). The
biofilm-inhibitory characteristic of C2DA makes it a potentially useful adjunct to antimicrobial therapy. Reports
of several medium- and long-chain fatty acids, including C2DA, indicate bactericidal or growth inhibitory
properties (77, 78). When combined with other antimicrobial therapeutics that are less successful against
biofilm, C2DA could improve overall antimicrobial efficacy (62).

Figure 1.2. Skeletal structure of cis-2-decenoic acid showing ten-carbon chain
backbone.

Current Therapies
Pain management strategies remain at the forefront of clinical needs, especially for musculoskeletal
injuries. Cocaine’s 1884 inception began the use of local anesthetics as pain management therapeutics (79). Not
only are local anesthetics used to mitigate pain, but during recent decades several studies have illustrated their
potential role as antimicrobials (79). Some anesthetics have exhibited fungistatic, fungicidal, bactericidal, and
bacteriostatic properties against a broad spectrum of microorganisms (80). During the same period, multiple
in vitro and in vivo studies have confirmed the auxiliary role of local anesthetics in SSI prevention and
treatment (79). Most of the studies over the past 30 years validating the antimicrobial effect of local anesthetics
have been in vitro (79). Reports of reductions in SSI rates are due to surgeon-directed therapies that include the
practice of applying local anesthetics on incision sites before incision, during incision, or at closure (81). The
LA antimicrobial in vitro properties combined with results indicating their efficacy in clinical practice warrants
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further investigation of their applications in preventing infection, particularly when combined with other
antimicrobials in local delivery systems.
Oral or intravenous drug delivery is well established; however, there are undesired effects, e.g.,
off-target consequences, reduced efficacy, and organ toxicity (82). Oral or intravenous antimicrobial therapy
must maintain inhibitory concentrations in infected tissue to be effective but should not exceed systemic levels
that are toxic to tissue (81). Local delivery devices loaded with antimicrobials are often implemented as an
adjunct to systemic antimicrobial therapy for open wound and fracture treatments. The overall goal of local
delivery is to achieve high local levels of bioactive antimicrobials with negligible serum levels and delivery
over extended periods until healing is complete (82). The elution or release of antimicrobials from the local
delivery system into the surrounding tissue depends on the delivery system matrix, surface area, volume, and
concentration of loaded antimicrobial (83). Systemically administered antimicrobials have low penetration into
bone; conversely, locally-delivered antimicrobials can achieve greater diffusion to bone and avascular wound
areas (81). Local antimicrobial delivery increases potency while simultaneously minimizing systemic toxicity
providing the basis for an improved delivery system (82).
Biodegradable delivery devices may improve local antimicrobial delivery efficacy with the added
advantage of being implanted at the wound site reducing delays between delivery and action. Biodegradable
devices are broken down naturally through hydrolytic mechanisms in the presence or absence of supplemental
enzymes. A principal advantage of locally delivered biodegradable devices is their ability to alleviate the need
for additional surgeries to remove the foreign antimicrobial delivery device. The current “gold standard” local
delivery systems include poly(methyl methacrylate) (PMMA) beads and spacers that do not biodegrade (83,
84). Alternatives to PMMA have been considered, including bioresorbable calcium sulfate, which could mix
with antibiotics before casting; however, these materials release high concentrations of antimicrobials that may
be toxic and lead to seroma formation (83).
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Chitosan is a linear polysaccharide composed of N-acetyl glucosamine and glucosamine repeat units
(85). Chitin, widely distributed in nature, is used to derive chitosan (86). Chitin, white, rigid, and inelastic, is a
natural polysaccharide composed of N-acetyl-glucosamine units isolated from the exoskeletons of arthropods,
e.g., crustaceans and insects, fungi cell walls, mollusks radulae, fish scales, cephalopod beaks, and
lissamphibian skin. One major procedure utilized to obtain chitosan involves subjecting the chitin polymer to a
strong alkaline solution that slowly removes acetyl groups from N-acetyl-glucosamine repeat units in a process
referred to as de-acetylation (87). Chitosan is distinguished from chitin by the number of remaining acetyl units.
Chitin has a degree of acetylation ranging from 0 - 50% compared to a degree of de-acetylation (DDA) for
chitosan of > 50%. Once DDA is > 50% the copolymer becomes chitosan. The DDA impacts how chitosan
performs (88, 89). Chitosan possesses a weak cationic base, is insoluble in water and organic solvents; however,
the polymer is soluble in dilute acidic conditions (86, 90). Chitosan has biodegradable (90-93) and antibacterial
(94) characteristics making it advantageous in drug delivery applications (91-93, 95).
Chitosan’s DDA affects degradability; when DDA is close to 50%, chitosan demonstrates high
degradability in vivo; however, when DDA is > 95%, chitosan may reside in vivo for months (90). Lysozyme,
N-acetyloglucosaminidase, and lipases degrade chitosan within the body (96). Lysozyme degrades chitosan
through cleavage of glycosidic bonds between repeating units, producing saccharides and glucosamines
byproducts, which are incorporated into glycoproteins or excreted as carbon dioxide (97). Chitosan’s
biodegradability allows implementation into local delivery systems for antimicrobials averting the need for
removal surgeries, reducing total cost and patient trauma, in direct contrast to comparable devices, e.g., PMMA
beads.
Currently, there are more than 200 applications or practical applications involving chitin, chitosan, or a
derivative (98-102). Applications include cosmetics, food, agriculture, biomedical, and textiles, to name only a
few. Medical applications for chitosan include utilization as wound dressings (103, 104), orthopaedic and
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craniofacial implant bioactive coatings (105, 106), and local drug delivery systems, amongst others (98, 99,
107-111). Chitosan local delivery systems have included vancomycin (107), amikacin (110), gentamicin (99),
prednisolone (109), daptomycin (110), recombinant human bone morphogenetic protein-2 (rhBMP-2) (98),
rifampin (112), and ciprofloxacin (112) among many others. Chitosan leads to rapid clot formation when
partially hydrated, providing potential usage as a bandage or hemostatic agent (99). When fully hydrated,
chitosan has properties allowing rapid rehydration and drug absorption (103).
Recent work involving nanofibrous chitosan-based biomaterials fabricated with an electrospinning
process offers advantages in drug delivery that may provide for extended-release of antimicrobials, mainly
when stabilized with hydrophobic modifications by acylation (113, 114). Chitosan-based biomaterials require
stabilization methods to be functional as a sustained local delivery device due to their pH levels. Sodium
hydroxide or acetate buffer stabilized previous chitosan-based biomaterials to increase pH to near neutral (112,
115, 116). Previous chitosan-based biomaterials, i.e., chitosan sponges and chitosan paste, were stabilized and
possessed functionality; however, they had limitations in their ability to load or release hydrophobic compounds
(112, 115, 117, 118). The electrospun nanofibers’ acylation techniques (113, 114) can extend to the broad range
of other chitosan-based biomaterials, such as particles or paste. Acylated nanofibrous biomaterials not only can
load hydrophobic compounds; once loaded, their elution kinetics extend (114), which would be advantageous
over the typical first-order release kinetics observed for other chitosan-based biomaterials (112, 115, 117).
Sustained-release promotes increased infection and biofilm inhibition.
Infected musculoskeletal wounds are challenging; specifically, those associated with biofilm, and they
present challenges to the healthcare system with ongoing research efforts to combat them. Current clinical
practices, including wound debridement, lavage, and fixation, may not be adequate to manage
biofilm-associated infections without systemic delivery, local antibiotic delivery, or the combination. Crucial
objectives for immediate management of traumatic musculoskeletal wounds or surgical site injuries include
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wound healing promotion, pain management, and infection prevention (38). Increasing numbers of SSIs and
growing antibiotic resistance are growing concerns in the fight against infections (45, 56). C2DA, along with
other biofilm inhibitors and dispersal agents, may increase antibiotic efficacy against biofilm and minimize
antimicrobial tolerance. Local anesthetics can provide localized and targeted pain relief along with
antimicrobial benefits, which may reduce the need for prescription or intravenous opioids. Local delivery of
antimicrobials using a biodegradable chitosan-based system offers a potential solution for delivering
antimicrobial and anesthetic molecules over extended periods as an adjunctive musculoskeletal wound
treatment.
Hypothesis
Chitosan-based biomaterials, modified by acylation, will form a cytocompatible and biocompatible local
delivery system capable of loading multiple hydrophobic therapeutics and deliver them for at least 72 hours. It
was also hypothesized that various local anesthetics and cis-2-decenoic acid would have antimicrobial efficacy
against numerous bacterial strains. Combined bupivacaine and C2DA delivery from modified chitosan paste
was expected to reduce infection when evaluated in an in vivo model effectively. Answers to these research
questions will characterize these biomaterials’ potential as adjunctive therapies for infection and biofilm
inhibition and the potential to provide localized targeted pain relief.
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2. CHAPTER 2
Synthesis and Characterization of 2-decenoic Acid Modified Chitosan for Infection
Prevention and Tissue Engineering

Introduction
Chitosan is considered a promising therapeutic delivery agent due to its biodegradability,
biocompatibility, non-toxicity, and inherent antimicrobial activity (1, 2). Chitosan is a
sugar-based biopolymer derived from exoskeletons of arthropods. Structurally, chitosan is a
heteropolymer composed of N-acetyl-D-glucosamine and D-glucosamine unit connected through
β (1-4) glycosidic bond. Chitosan has three reactive functional groups: an amine group at the C-2
position and primary and secondary hydroxyl groups at C-6 and C-3 positions, respectively.
Chitosan is polycationic at a pH below six and interacts with negatively charged molecules, such
as proteins, anionic polysaccharides, fatty acids, bile acids, and phospholipids (3). Chitosan is a
versatile biopolymer due to its flexibility that allows manufacturing into various forms such as
gels, nanofibers, pastes, films, etc. Electrospun chitosan membranes are of particular interest for
biomedical applications due to their porous nanofibrous structure and high surface area that
mimics the extracellular matrix. Multiple biomedical applications, including wound dressings,
drug delivery, and tissue engineering, involve nanofibrous chitosan membranes (4, 5).
Chemical modification of electrospun chitosan membranes can enhance their
physicochemical properties, further functionalizing the material to allow for a broader range of
applications. For example, the incorporation of hydrophobic substituents such as fatty acids
generates a domain for absorbing and carrying poorly soluble drugs. Literature supports fatty
acid (FA)-treated electrospun chitosan membranes' ability to control the hydrophobic drug
simvastatin release (6). Linoleic and α-linolenic acid-modified chitosan has demonstrated
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potential as a multifunctional catheter coating by improving the lubricity and antimicrobial
properties (7). A study also found that fatty acid incorporated chitosan can improve the
self-nano-emulsifying drug delivery system's mucoadhesive property (8). Studies investigated
decanoic acid grafted chitosan as a potential carrier of insulin by combining the mucoadhesive
and permeative properties of chitosan and decanoic acid, respectively (9). Decanoic, oleic, and
linoleic acid-modified chitosan have enhanced wound healing rates (10, 11). The length of the
fatty acyl chain incorporated through O-acylation improves its stability in the moist environment
while maintaining its non-toxic property and has shown promise for regenerating bone in guided
bone regeneration (GBR) applications in rodent models (12-14). A study using buriti oil
containing volatile compounds and fatty acids indicated that chitosan and buriti oil could be
combined into a gel to improve chemical properties and activity against Gram-negative
pathogens (15). Besides the antimicrobial activity, chitosan gel with buriti showed antioxidant
and anti-inflammatory properties, good healing activity, and an adequate wound retraction rate
(15).
Trifluoroacetic acid (TFA) is one of the most commonly used solvents for
electrospinning chitosan membranes because it provides adequate viscosity for the polymer
solution to be pulled into nanofibers (6, 16). Despite this benefit, TFA forms a salt with
chitosan's amino groups, requiring removal without compromising the nanofibrous structure or
deteriorating the membrane's mechanical properties. One technique to achieve this balance
involves grafting FA groups to the hydroxyl groups outside of the chitosan fibers to create a
hydrophobic covering to prevent fiber swelling during subsequent washing steps to remove TFA
ions (13). FA chains can be attached to any of the three reactive groups; acid chlorides and
methanol crosslink FAs in the amine position (17, 18). Acylation reactions may also use a
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coupling agent such as 1-ethyl-3-(3-dimethyl-aminopropyl)-1-carbodiimide hydrochloride
(EDC) to improve the reactivity (7). The TFA salt in the electrospun chitosan membrane
occupies the amine group (16). Wu et al. developed an O-acylation method in which the chitosan
membrane is acylated by acid anhydride in the presence of a pyridine catalyst to improve its
stability in an aqueous solution (12, 14). Attempts to incorporate fatty acyl chains before
electrospinning the membrane resulted in non-uniform size and distribution of the fibers; due to
steric hindrance of the long FA chain in uniform and fine formation fibers (19-21).
The fatty acid 2-decenoic acid (2DA) and its analogs are medium-chain FA chemical
messengers naturally produced by bacteria. Studies have shown that the cis- form of 2DA
(C2DA) disperses existing biofilm and inhibits biofilm formation (22). Studies suggest that 2DA
could increase microbes' metabolic activity and the bactericidal ability of commonly used
antimicrobials (23). These properties could make 2DA a potential complementary therapy for
infection. Additionally, 2DA could lessen antibiotic tolerance by improving the efficacy of these
drugs against biofilm infection. Acylating chitosan membranes with 2DA or analogs may
provide the advantages of bacterial biofilm resistive materials and the ability to load with
hydrophobic therapeutics for extended-release. However, chlorides or anhydrides of 2DA are not
commercially available. This study investigates a custom-synthesis route for acyl chlorides and
their ability to stabilize and functionalize chitosan nanofibers. Additionally, it determined
physicochemical properties, antimicrobial properties, and cytocompatibility (24).
Materials and Methods
Fabrication of Electrospun Membranes
Nanofibrous chitosan membranes were electrospun using Primex (Iceland) chitosan
(71% DDA, 311.5 kDa). Chitosan was dissolved overnight at 5.5% (w/v), of 70:30% (v/v) TFA
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and dichloromethane (DCM) purchased from Sigma Fisher (USA). The 10 mL solution was
centrifuged to remove any insoluble chitosan, transferred to a syringe with a 20gauge blunt
needle, and electrospun at a rate of 15 mL min-1 and a voltage of 27 kV using a syringe pump
onto an aluminum foil covered collector plate rotating at ~8.4 revolutions per minute, with
constant monitoring of the Taylor Cone to ensure high-quality membranes. The electrospinning
apparatus was housed inside a ventilated box which was vented to the fume hood. The apparatus
was operated at room temperature and 40 to 60% humidity, using humidity monitors and
humidifiers. Membranes were spun from three 10 mL volumes to obtain a diameter of 15 cm and
a thickness of approximately 700 nm. After membranes were fabricated, 10 mm diameter discs
were punched out for use in experiments.
Synthesis of 2-decenoyl Chloride
A reflux reaction was used to synthesize 2-decenoyl chloride by first placing 1 M
(40 g L-1) of sodium hydroxide (NaOH) in a covered beaker on ice. The NaOH beaker was then
connected to a condenser unit in a water bath set at 35 °C. First, 150 mmol thionyl chloride was
added to a three-neck round bottom flask. Second, while slightly shaking the flask, 100 mmol of
2-decenoic acid was added. Once both compounds were in the flask, the flask was connected to
the condenser system, sealed, and reacted for five hours. After reaction completion, the
synthesized 2-decenoyl chloride was removed from the flask and stored until later use. Decanoyl
chloride (DC) and hexanoyl chloride (HC) were purchased from Sigma Fisher (USA).
Acylation Reactions
The direct acylation of chitosan materials by acyl chlorides was achieved by first making
a 5 mg mL-1 solution of chitosan material in pyridine. With a ratio of 3:1 (v/v) pyridine to acyl
chloride, the acyl chloride was slowly added while stirring. The solution reacted for 1.5 hours.
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Once the reaction was complete, the chitosan materials were removed and 1) placed in 10%
acetone solution (1 L), 2) removed and placed in 70% ethanol solution, and 3 - 5) removed and
placed in deionized water (DI) each step lasted for at least one hour. After the final washing step,
the chitosan materials were removed from the solution, placed flat onto a glass surface, and
frozen at -80 °C. The frozen materials were lyophilized. After lyophilization, the materials were
stored in a desiccator until further analysis.
FTIR
Attenuated Total Reflectance (ATR) Fourier Transform Infrared (FTIR) spectra were
collected using an FTIR spectrometer, Frontier (Perkin-Elmer, USA). ATR spectra were
collected to confirm the attachment of FA groups to the chitosan polymer chain and TFA salt
removal by the treatments.
Contact angle
Water contact angles of modified membranes were determined using a VCA optima
measurement machine (AST products, INC, USA). Water droplets (5 μL) were placed carefully
onto the membrane surfaces. A digital camera recorded the photographs of the droplets after
approximately one minute. The goniometry software of VCA OptimaXE calculated the contact
angles. For each modification, four different membranes were tested at three regions.
Cytocompatibility
NIH 3T3 (American Type Culture Collection) fibroblasts were seeded at a concentration
of 104 cells cm-2 in a 24-well plate in Dulbecco’s Modified Eagle’s Medium (DMEM) high
glucose supplemented with 10% fetal bovine serum (FBS, Gibco) and 2% (100 µg mL-1)
Normocin (InvivoGen, San Diego, CA). Chitosan membranes were placed into well inserts and
then immersed into the wells containing cells and media. Plates were incubated at 37 °C with 5%
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carbon dioxide (CO2). Every 24 hours, the inserts were removed, the wells were bright field
imaged, and the media was refreshed. Controls with no membranes were used to normalize the
cells’ viability percentage. After 48 hours, viability was determined using CellTiter-Glo®
(Promega) and expressed as a percentage of tissue culture plastic controls.
Antimicrobial Activity
Pseudomonas aeruginosa (P. aeruginosa, ATCC #27317) and Staphylococcus aureus
(S aureus, UAMS-1, a clinical osteomyelitis strain) grown overnight were diluted to 1:50 and
1:10 respectively. Diluted bacteria (500 μL) were added to the well containing HC, DC,
trans-2-decenoic acid (T2DA) chloride modified membranes, sponge, or gauze, and incubated
for 24h. The membranes, sponges, and gauzes were taken out of the solution after the incubation
period and washed three times with 500 μL of 1X phosphate-buffered saline (PBS). They were
then immersed in 500 μL of sterilized tryptic soy broth (TSB) and sonicated for 5 min to detach
the bacteria. After sonication, the detached bacteria solution was used for colony forming unit
(CFU) counting by plating dilutions.
Statistical Analysis
SigmaPlot and GraphPad Prism 7.2 software (GraphPad Software Incorporation, La Jolla,
CA, USA) was used to perform the statistical analysis. Data was assessed first by performing
Shapiro-Wilk normality test, followed by Brown-Forsythe equal variance test. If both passed, a
one-way analysis of variance (ANOVA) further analyzed the data, followed by Holm-Sidak’s
post-hoc analysis to detect significance between experimental groups (α = 0.05). Kruskal-Wallis
ANOVA on ranks, followed by Tukey post-hoc test, completed additional analysis if necessary
normality and equal variance requirements did not occur.
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Results
Fabrication
Scanning Electron Microscope (SEM) images showed that fibers formed and stabilized with
each acylation method without significant swelling when compared to the fibers of an
unmodified nanofibrous chitosan membrane (Figure 2.1).

Figure 2.1. SEM micrographs of (A) unmodified, (B) HC modified, (C) HC modified, and (D) T2DA modified
membranes.

FTIR
FTIR analysis comparing chitosan membranes with various acylation treatments confirms
a presence of an ester carbonyl group on the treated membranes (peak at 1750 cm-1), indicating
successful acylation for all three modifications (Figure 2.2). Peaks around 2900 cm-1 also
confirm alkyl chains at the surface of the treated membranes, with increased intensity with
increasing FA chain lengths. The two peaks around 3300 and 3500 cm−1 for DC modified and
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HC modified membranes represent NH2. The lack of peaks < 1000 cm-1 in treated membranes
confirms the removal of TFA salts.

Figure 2.2. FTIR spectra of chloride modified and unmodified nanofibrous chitosan membranes.

Contact angle
Water droplets remained stable on hexanoic-acylated membranes for 3 - 5 minutes,
whereas for decanoic-acylated and 2-decenoic-acylated, the drop remained stable even after
15 min. Among all the treatments, 2-decenoic-acylated membranes were the most hydrophobic
(121.50° ± 6.2°) as seen in Table 2.1.
Table 2.1. Water contact angle measurement (mean ± standard deviation) of modified
membranes (n = 3).

Membrane Modification
HC
DC
2-decenoic

Water contact angle (°)
74.10°± 3.5*
93.20°± 5.6*
121.50° ± 6.2*

* indicates statistically different groups, p < 0.05
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Antimicrobial activity
The sponge control had significantly more P aeruginosa CFUs counted than all other
groups (Figure 2.4). The CFU count for hexanoic modified membranes was similar to the CFU
count for the gauze control; however, the CFU counts for decanoic modified and 2-decenoic
modified membranes was noticeably less than the gauze and sponge controls for S aureus
(Figure 2.4) and P. aeruginosa (Figure 2.5).
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Figure 2.3. Colony forming units (mean ± standard deviation) of
S. aureus on the modified chitosan membranes (n = 3). No statistically
significant differences were detected.
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P. aeruginosa CFUs
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Figure 2.4. Colony forming units (mean ± standard deviation) of
P. aeruginosa on the modified chitosan membranes (n = 3). * indicates
significant difference (p < 0.05) between sponge and denoted groups.

SEM images of biofilm attached to membranes confirmed that some sparse colonies of
S. aureus exist on hexanoic- and decanoic-acylated membranes, with very few observed on
2-decenoic membranes. P. aeruginosa formed abundant exopolymeric substance (EPS) on gauze
fibers (Figure 2.6). In contrast, while P. aeruginosa subsisted on acylated membranes, EPS
formation was minimal.

Figure 2.5. SEM micrographs of biofilms attached to gauze and modified chitosan membranes. The chitosan sponge is not
shown due to issues relating to the critical point drying procedure.
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Cytocompatibility
When exposed to membranes modified by acyl chlorides, the percent viability of cells
showed no significant differences, and all were above the ISO standard 70% cytocompatibility
threshold (25), denoted by the black line (Figure 2.7).
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Figure 2.6. Graph shows cytocompatibility testing of acyl-chloride
modified membranes (n = 3) in transwell in contact with NIH 3T3 cells.

Discussion
The study results show the initial success of the acyl chloride synthesis and chitosan
modification process. Synthesized chlorides are customizable, making previously commercially
unavailable compounds accessible for acylation processes. Synthesized chlorides can modify
various chitosan-based biomaterials’ properties in a nondetrimental way, particularly in that the
functionalization imparts hydrophobic properties that limit bacterial attachment and may also
allow loading and release of therapeutics (6, 7). Acidic hydrochloride salt formulations are not
necessary for loading local anesthetics in acylated chitosan biomaterials. The ability to
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synthesize chlorides that are not commercially available could expand the possible applications
to other fatty acid analogs, including cis-2-decenoic acid and 2-heptylcyclopropane-1-carboxylic
acid, to expand possible antimicrobial solutions in the continuing fight against antibiotic
resistance and complex biofilm-associated infections.
FTIR results indicate immobilization of FAs on the fibers. The absorption peak around
1750 cm-1 representing the acyl group (C = O) and ester bond formation confirms acylation.
Ester bonds may be particularly advantageous for these materials in infection prevention. In the
presence of acidic environments such as those found locally at tissue injury sites or in the
presence of bacterial enzymes, such as lipase, they may hydrolyze (22, 23).
Environment-influenced hydrolysis may cause acylated chitosan biomaterials to be less reactive
until interaction with bacteria or damaged tissue. This study did not measure the hydrolysis rate
of fatty acids; future studies will investigate whether conjugated 2DA release is lipase- or
pH-sensitive. FTIR spectra broad peaks at 3100 - 3500 cm-1 represent inter- and intra-molecular
hydrogen bonding of the —NH2 and —OH vibration stretching of chitosan molecules (13). Of
note, TFA salt representative transmittance peaks at 720, 802, and 837 cm-1 are not present in
any of the modified chitosan biomaterials that confirm the salts are no longer present.
Water contact angle provides a preliminary validation of the introduced hydrophobic
properties to the hydrophilic chitosan biomaterial. The contact angle results for this study using
acyl chlorides are consistent with prior studies that used acyl anhydrides (6) in that the contact
angle increases with the chain length. Decanoic and 2-decenoic acids have the same chain length,
with 2DA having one unsaturated bond. However, the unsaturated fatty acid should have less
hydrophobicity than the saturated decanoic acid. The differences in contact angle observed in
this evaluation may be due to varying degrees of substitution. Introducing hydrophobic
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properties to biomaterials may affect protein adsorption properties, improve hydrophobic
compounds’ elution kinetics, and stabilize structures. Previous investigations produced numerous
chitosan-based biomaterials that can load and deliver hydrophilic therapeutics, e.g., paste and
sponges (26-30). The acylation modification strategy may enable improved hydrophobic
molecule usage with the same chitosan-based biomaterials, which past hydrophobic molecule
inclusion proved to be a challenge (31).
Fibers did not significantly swell after the acylation process, as evident by SEM analysis.
Being able to maintain nanofibrous structure is critical to the development and function of this
chitosan biomaterial. Future studies will need to address these limitations to improve the chances
for modified chitosan biomaterials’ use in specific clinical applications. Future studies will use
more materials characteristic methods, i.e., NMR, to determine structure and base catalysis
methods to conclude the degree of substitution.
Acylated chitosan membranes demonstrated the ability to inhibit bacterial growth and
attachment (CFUs). In all antimicrobial testing conditions, the acylating nanofibers showed
evidence of reduced biofilm attachment. The modified materials’ degree of substitution is one
potential characteristic that reinforces the demonstrated inhibition. Surface attachment is one of
the biofilm mechanisms to develop and persist. Modified chitosan nanofibrous membranes have
more surface area for bacteria to attach than chitosan sponge or gauze and still produced better
bacteria inhibition results. These findings support the hypothesis that acyl-modification
contributes to improved material antimicrobial properties. Acyl-modified materials seem to
inhibit P. aeruginosa EPS production. Reducing EPS secretion from P. aeruginosa blocks a
primary mechanism P. aeruginosa uses to form a biofilm, and modified materials may interfere
with type IV pili (32-34). S. aureus biofilm inhibitory effects may be due to interference with
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microbial surface components recognizing adhesive matrix molecules (MSCRAMM).
MSCRAMMs are instrumental in S. aureus attachment and subsequent biofilm formation (35).
When unattached bacteria remain in the planktonic state longer, they are more susceptible to
antimicrobials and the innate immune system. This study chose S. aureus and P. aeruginosa as
representative Gram-positive and Gram-negative strains that are common pathogenic strains in
bone and wound injuries. The modified membranes’ efficacy against other bacterial and fungal
strains is necessary to understand their broad antimicrobial efficacy.
Bacterial inhibition without maintaining cyto- and bio-compatibility invalidates any potential
antimicrobial therapy. All acyl-modified materials demonstrated cytocompatibility with no
statistical significance between any of the evaluated groups. All modified membranes met or
exceeded the minimum 70% cellular compatibility threshold. Future studies will evaluate the
effects of these materials on other cell types, such as immune cells, and assess biocompatibility
in vivo . While this study did not assess unmodified material as controls, the acyl-modified
materials performed similarly to previously investigated chitosan-based materials (6, 27, 36).
There are no signs of acyl-modified materials adversely affecting cells or any signals that healing
would be negatively affected (10). The modified nanofibers’ bacterial inhibitory effects would be
advantageous in clinical applications involving wound dressings or wraps, bone scaffolds, or
guided tissue regeneration membranes, among others.
In summary, modified chitosan biomaterials possess characteristics that support their use
in infection prevention treatment strategies. We can functionalize chitosan with a specific fatty
acid which may have applicability to other fatty acid conjugation with our synthesis route. Future
studies will evaluate conjugated fatty acid hydrolysis rate in physiological relevant solutions,
including acidic and in the presence of enzymes, e.g., lipase. Additional future and ongoing
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studies will characterize the modified materials’ drug delivery capabilities, including therapeutic
loading and release, including but not limited to local anesthetics, statins, chemotherapeutics, and
antimicrobials.
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3. CHAPTER 3
Antimicrobial and Anti-biofilm Efficacy of Local Anesthetics Combined with
Cis-2-decenoic Acid against Staphylococcus Aureus, Pseudomonas Aeruginosa, and
Acinetobacter Baumannii

Introduction
Infections related to traumatic musculoskeletal wounds often are challenging to treat and
painful, requiring multiple surgeries while increasing patient morbidity, costs, and treatment
time. Traumatic injuries often involve numerous tissues susceptible to environmental
contamination, and wounds such as open bone fractures and burns are particularly at risk for
infection (1, 2). Microorganisms can enter injured tissue through the patient’s microflora or
contact with the environment or healthcare workers (3, 4), i.e., patient to patient, hospital
environment, and fomites, or unwashed hands (5). Osteomyelitis infections can be particularly
devastating to the healthcare system and deemed incurable due to deep bacterial persistence (6).
Complex wound infections resulting from burns account for approximately 51% of burn-related
deaths (2). Traumatic complex extremity injuries have increased susceptibility to multiple
pathogenic and multi-drug resistant bacterial strains, including methicillin-resistant
Staphylococcus aureus (MRSA), Pseudomonas aeruginosa, and Acinetobacter baumannii (7, 8).
Gram-positive Staphylococcus aureus (S. aureus) is the predominant pathogen in orthopaedic
infection (9) and contributes to approximately 50% of burn wound infections (10). In addition to
Gram-positive microorganisms, Gram-negative microorganisms, such as P. aeruginosa and
A. baumannii, often contaminate soft tissue injuries and burns (11).
Systemic antibiotics, the current prophylaxis, and treatment for infections require high
doses due to traumatic wound sites' avascular areas. Upon injury, the skin's protective
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mechanisms (i.e., defensins from keratinocytes and acidic secretions from sebaceous glands) are
severely impaired or lost entirely, allowing microorganisms to colonize and form a biofilm
rapidly (12). With complex traumatic injury and the accompanying reduced blood supply along
with the limited systemic antibiotic diffusion, bacteria, especially biofilm-forming bacteria, can
be highly tolerant to low levels of antimicrobials due to a combination of semi-dormant persister
cells, exopolymeric substance (EPS) secretion, and metabolic adaptations (3, 13). Studies have
shown that P aeruginosa isolates from a burn wound developed EPS within 5 hours and has the
characteristics of a mature biofilm within 10 hours, demonstrating the necessity of taking
immediate preventative measures after injury (14). Furthermore, clinical studies showed that
while debridement of burn wounds could remove biofilm from wound beds, biofilms recolonized
two days after this initial debridement (15). Similarly, orthopaedic implant-associated infections
managed with debridement and irrigation with retention (DAIR) of the implant have high
infection recurrence rates, in part due to biofilm formation (16, 17). Each of these studies
indicates the need for prompt and sustained non-antibiotic methods to treat and prevent biofilm
in wounds.
Musculoskeletal trauma also causes significant pain for patients. Due to the recent opioid
misuse and addiction epidemic, non-opioid pain management strategies are of great clinical
interest (18). Local anesthetics (LA) block voltage-gated sodium channels, temporarily blocking
nerve conduction through nociceptive afferent nerves and subsequently numbing local pain (19).
Their chemical structure typically consists of a hydrophobic aromatic group linked via an
intermediate ester or amide chain to a hydrophilic amine group (20). In addition to their
pain-relieving ability, some LA, including bupivacaine (BUP), ropivacaine (ROP), and lidocaine
(LID), also have reported antimicrobial capabilities (21). A previous in vivo study on a topical
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local anesthetic spray against mixed microflora of the oral cavity showed a time-dependent effect
of 10% LID on certain bacterial strains, mostly Gram-negative (22). The study reduced the
number of oral biofilms on the buccal mucosa by 60–95% compared to a group without LA (22).
Additionally, an infection mice model study showed an almost 10-fold reduction in CFUs
of S. aureus compared to a saline control after 48 hours of continuous 2% LID infusion (23).
Few studies have investigated the effects of LA against biofilm. However, Gil et al. recently
reported that polyethylene loaded with BUP-hydrochloride had a dose-dependent inhibitory
effect on S. aureus biofilm formation (24). Many studies investigating LA's antimicrobial
characteristics use commercial preparations of hydrochloride salts, which can be acidic and
confound results.
Biofilm-associated bacteria use quorum sensing to communicate with each other, reduce
metabolic activity, and produce polysaccharide EPS, which allow the bacteria to evade innate
immune activity and most antimicrobials. Treating established implant biofilms has proven to be
virtually impossible without surgical intervention, which places additional burdens on patients,
insurance companies, and the healthcare system. Cis-2-decenoic acid (C2DA) is a medium-chain
fatty acid that disperses and inhibits biofilm (8, 25). C2DA induces the biofilm dispersion
response native to many Gram-negative and Gram-positive bacteria and yeast, reverses biofilms'
persistence, increases the metabolic activity of microbials, and significantly enhances the -cidal
effects of conventional antimicrobial agents (26, 27). In a previous analysis, C2DA
concentrations ≥ 500 μg mL-1 inhibited planktonic growth, while 125 μg mL-1 C2DA inhibited
biofilm (25). There were no adverse cytocompatibility effects on fibroblasts at these
concentrations (25). Studies by Rahmani-Badi et al. demonstrated that combining the
biofilm-active C2DA with antibiotics or antimicrobials enhances the activity against biofilm (28,
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29). Additive and synergistic effects of C2DA combined with common antimicrobials were
reported by Masters et al., particularly for antibiotics with mechanisms of action internal to the
cell membrane (30). This study's objective was to evaluate different LA molecules on pathogenic
microorganisms that commonly contribute to an infection and determine whether combining LA
with C2DA has additive, synergistic, or antagonistic effects against planktonic and
biofilm-associated S. aureus, P. aeruginosa, and A. baumannii.
Materials and Methods
Checkerboard assays
S. aureus (UAMS-1, a clinical osteomyelitis strain) overnight growth was diluted 1:10 in
tryptic soy broth (TSB). P. aeruginosa (ATCC #27317) and A. baumannii
(ATCC #BAA-1710™) overnight growths were diluted 1:50 in TSB. Antimicrobials tested
included bupivacaine (Alfa Aesar™), lidocaine (TCI America™), ropivacaine (Alfa Aesar™),
and C2DA, with the final LA concentrations ranging from 0 - 10 mg mL-1 and C2DA from
0 - 500 mg mL-1. Due to the hydrophobic characteristics of LAs and C2DA, they were
solubilized in 200 proof ethanol and added to bacterial culture in amounts that diluted
concentrations to 2.5% ethanol in TSB. ROP still required the addition of 6.25 mM HCl due to
solubility issues in 100% ethanol. Bacteria and antimicrobial solutions were added to 96-well
plates and incubated for 24 hours.
Planktonic growth
General antimicrobial activity of LA, C2DA, and combinations against planktonic
bacteria was determined by concurrently inoculating 96-well plates with bacteria. Wells were
inoculated with 106 CFUs of S. aureus, P. aeruginosa, or A. baumannii, then combined with LAs
(0, 0.3125, 0.625, 1.25, 2.5, 5, or 10 mg mL-1), C2DA (500 mg mL-1), or combinations. After 24
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hours of incubation, 100 µL of planktonic growth was removed, and BacTiter-Glo™ viability
reagent was used to determine bacterial survival. Luminescence was determined using a
Biotek Synergy™ H1 microplate reader, with increased luminescence indicating a higher
number of viable cells. Percent viability was determined using the control with PBS only.
Biofilm growth
After removing TSB with planktonic growth, biofilm attached to plates was gently rinsed
three times with sterile PBS. BacTiter-Glo™ viability reagent was used to compare biofilm
viability on polystyrene plates after exposure to the therapeutics. A Biotek Synergy™ H1
microplate reader determined luminescence, with increased fluorescence indicating a higher
number of viable cells. Percent viability was determined using the control with PBS only.
Fractional Inhibitory Concentration
The fractional inhibitory concentration index (FICI) was calculated using the
concentrations alone (S) and in combination (C) that reduced viability to under 10% of
non-treated controls. FICI is determined using the ratio of minimum biofilm inhibitory
concentration (MBIC) for the antimicrobial alone to the MBIC for the antimicrobial in
combination with C2DA was added to the ratio of MBIC for C2DA alone to MBIC of C2DA
when combined with antimicrobial (Equation 3.1) (31). The lowest antimicrobial concentration
that inhibits biofilm growth determines the MBIC. Minimum inhibitory concentration (MIC) is
determined using the same calculation except for planktonic growth. Synergism occurs when the
antimicrobials' effect is greater than the sum of their effect individually or when the FICI is less
than one. Antagonism occurs when the antimicrobials' effect reduces when combined or when
the FICI is greater than two. A FICI value of two represents neither improvement nor reduction
in effectiveness with the combination of antimicrobials. Following similar studies (32, 33), we
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considered FICI values < 0.5 synergistic, ³ 0.5 - < 1 additive, ³ 1 - < 2 indifferent, and ³ 2
antagonistic. The FICI was calculated separately for each bacterial strain.
𝐹𝐼𝐶𝐼 =

𝑀𝐵𝐼𝐶/𝑀𝐼𝐶!"($) 𝑀𝐵𝐼𝐶/𝑀𝐼𝐶$'("($)
+
𝑀𝐵𝐼𝐶/𝑀𝐼𝐶!"(&) 𝑀𝐵𝐼𝐶/𝑀𝐼𝐶$'("(&)

Equation 3.1. Fractional Inhibitory Concentration Index (FICI)
calculation using the concentrations alone (S) and in
combination (C).

Statistical analysis
GraphPad Prism 9.0.0 software (GraphPad Software Incorporation, La Jolla, CA, USA)
performed the statistical analysis. Data was assessed first by completing the Shapiro-Wilk
normality test, followed by the Brown-Forsythe equal variance test. If both passed, data were
further analyzed with a two‑way analysis of variance (ANOVA) followed by Holm-Sidak
post-hoc analysis to detect significance between experimental groups (α = 0.05).
Results
Planktonic growth
For S. aureus, there was a decrease in viability for all groups as LA concentration
increased; however, BUP reduced the planktonic viability more than LID and ROP and at lower
concentrations than the other LAs (Figure 3.1). Combining LAs with C2DA significantly
decreased planktonic S. aureus viability for wells treated with LID and ROP and slightly reduced
viability for wells treated with BUP (Figure 3.2).
ROP did not reduce A. baumannii planktonic growth even at increasing therapeutic
concentrations. BUP appeared more efficacious against A. baumannii at lower concentrations
than the other LA, but BUP and LID were equally effective at 10 mg mL-1 (Figure 3.3). Overall,
LAs were more efficacious in planktonic viability reduction than C2DA alone or in combination
with C2DA for all groups (Figure 3.4).
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Finally, all LA demonstrated activity against P. aeruginosa and had similar viability
percentages at all concentrations (Figure 3.5). C2DA alone was the least active against
P. aeruginosa than the other strains, but all LAs effectively prevented planktonic bacterial
growth (Figure 3.6). The combination of C2DA and LA reduced planktonic viability compared

Planktonic Viability (%)

to C2DA alone, but planktonic growth was still higher with the combination than with LA alone.
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Figure 3.1. Mean standard ± deviation of S. aureus planktonic viability of local
anesthetics alone (n = 3).
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Figure 3.2. Mean standard ± deviation of S. aureus planktonic viability of local
anesthetics alone (5 mg mL-1), C2DA alone (500 mg mL-1), and in combination
(5 mg mL-1 and 500 mg mL-1), respectively (n = 3).
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Figure 3.3. Mean standard ± deviation of A. baumannii planktonic viability of local
anesthetics alone (n = 3).

47

Planktonic Viability (%)

250

Local Anesthetic
C2DA
Local Anesthetic & C2DA

200
150
100
50
0

Bupivacaine

Lidocaine

Ropivacaine

Planktonic Viability (%)

Figure 3.4. Mean standard ± deviation of A. baumannii planktonic viability of local
anesthetics alone (5 mg mL-1), C2DA alone (500 mg mL-1), and in combination
(5 mg mL-1 and 500 mg mL-1), respectively (n = 3).
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Figure 3.5. Mean standard ± deviation of P. aeruginosa planktonic viability of local
anesthetics alone (n = 3).
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Figure 3.6. Mean standard ± deviation of P. aeruginosa planktonic viability of local
anesthetics alone (5 mg mL-1), C2DA alone (500 mg mL-1), and in combination
(5 mg mL-1 and 500 mg mL-1), respectively (n = 3).

Biofilm growth
The biofilm viability of S. aureus was similar for BUP and LID and slightly higher for
ROP compared to other LAs (Figure 3.7). The combination of C2DA and LA significantly
reduced S. aureus biofilm viability with BUP and ROP but had no reducing effect with LID
(Figure 3.8).
LID reduced A. baumannii biofilm growth the most effective, compared to BUP and
ROP, which had similar reduction trends (Figure 3.9). While C2DA alone was ineffective at
biofilm viability reduction, LA alone and in combination with C2DA showed a significant
decrease in viability, especially for BUP and LID (Figure 3.10).
All LAs alone were mostly ineffective at P. aeruginosa biofilm reduction, with little
change in biofilm viability with LA concentration changes (Figure 3.11). Additionally, LAs
combined with C2DA did not significantly reduce P. aeruginosa biofilm viability (Figure 3.12).
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Figure 3.7. Mean standard ± deviation of S. aureus biofilm viability of local anesthetics
alone (n = 3).
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Figure 3.8. Mean standard ± deviation of S. aureus biofilm viability of local anesthetics
alone (5 mg mL-1), C2DA alone (500 mg mL-1), and in combination (5 mg mL-1 and
500 mg mL-1), respectively (n = 3).
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Figure 3.9. Mean standard ± deviation of A. baumannii biofilm viability of local
anesthetics alone (n = 3).
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Figure 3.10. Mean standard ± deviation of A. baumannii biofilm viability of local
anesthetics alone (5 mg mL-1), C2DA alone (500 mg mL-1), and in combination
(5 mg mL-1 and 500 mg mL-1), respectively (n = 3).

51

Planktonic Viability (%)

150

Bupivacaine
Lidocaine
Ropivacaine

100

50

0

0.3125 0.6250 1.2500 2.5000 5.0000 10.0000

Concentration (mg mL-1)
Figure 3.11. Mean standard ± deviation of P. aeruginosa biofilm viability of local
anesthetics alone (n = 3).
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Figure 3.12. Mean standard ± deviation of P. aeruginosa biofilm viability of local
anesthetics alone (5 mg mL-1), C2DA alone (500 mg mL-1), and in combination
(5 mg mL-1 and 500 mg mL-1), respectively (n = 3).

FICI
LAs did not reduce S. aureus planktonic or biofilm viability below the 10% threshold
when tested alone. Figures 3.1 and 3.2 demonstrate the effect of using the LA in combination
with C2DA, graphically represented concentrations are LA (10 mg mL-1) and C2DA
(500 mg mL-1). In most instances, the combination’s reduction was more significant than either
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LA or C2DA tested singularly. BUP and ROP are synergistic, with additive effects for LID
combined with C2DA against planktonic S. aureus. Tables 3.1, 3.2, and 3.3 show MIC and
MBIC values used in the calculations. BUP demonstrated an additive effect with C2DA against
S. aureus biofilm, with other LAs being indifferent. Since no LA nor C2DA reduced viability
below 10% at their highest concentrations alone, 2x those concentrations were used in FICI
calculations when necessary. This study did not directly evaluate values that exceeded LA
solubility limits or C2DA’s critical micelle concentration. No statistically significant differences
were present for LAs when tested against Gram-positive S. aureus. BUP accounted for more than
50% of statistically significant differences for the Gram-negative bacterial strains (Tables 3.4
and 3.5).
Tables
Table 3.1. MIC and MBIC values (mg mL-1) used in FICI calculations for tested local anesthetics and C2DA, evaluated alone (S)
or in combination (C) against S aureus.
Biofilm
MBIC
BUP
ROP
LID

Planktonic
MIC

C2DA
(S)

C2DA
(C)

LA
(S)

LA
(C)

FICI

Interpretation

C2DA
(S)

C2DA
(C)

LA
(S)

LA
(C)

FICI

Interpretation

1
1
1

0.25
1
1

10
20
20

5
20
20

0.75
2
2

Additive
Indifferent
Indifferent

1
1
1

0.25
0.031
0.25

20
10
20

2.5
0.625
5

0.375
0.094
0.5

Synergistic
Synergistic
Additive

Table 3.2. MIC and MBIC values (mg mL-1) used in FICI calculations for tested local anesthetics and C2DA, evaluated alone (S)
or in combination (C) against A baumannii.
Biofilm
MBIC

BUP
ROP
LID

Planktonic
MIC

C2DA
(S)

C2DA
(C)

LA
(S)

LA
(C)

FICI

Interpretation

C2DA
(S)

C2DA
(C)

LA
(S)

LA
(C)

FICI

Interpretation

1
1
1

0.25
1
1

10
10
10

2.5
10
10

0.5
2
2

Synergistic
Indifferent
Indifferent

1
1
1

0.5
0.25
1

10
10
10

5
1.25
10

1
0.375
2

Additive
Synergistic
Indifferent
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Table 3.3. MIC and MBIC values (mg mL-1) used in FICI calculations for tested local anesthetics and C2DA, evaluated alone (S)
or in combination (C) against P aeruginosa.
Biofilm
MBIC
BUP
ROP
LID

Planktonic
MIC

C2DA
(S)

C2DA
(C)

LA
(S)

LA
(C)

FICI

Interpretation

C2DA
(S)

C2DA
(C)

LA
(S)

LA
(C)

FICI

Interpretation

1
1
1

0.25
1
1

10
10
10

2.5
10
10

0.5
2
2

Synergistic
Indifferent
Indifferent

1
1
1

0.5
0.25
1

10
10
10

5
1.25
10

1
0.375
2

Additive
Synergistic
Indifferent

Table 3.4. Local anesthetics’ statistically significant results of A. Baumannii planktonic and
biofilm growth.
Bacteria State

Planktonic

Biofilm

Comparison
BUP v. LID
BUP v. ROP
BUP v. LID
BUP v. ROP
LID v. ROP
BUP v. LID
BUP v. LID
BUP v. ROP
LID v. ROP
LID v. ROP
BUP v. LID
LID v. ROP
BUP v. LID
LID v. ROP
BUP v. LID
LID v. ROP
BUP v. ROP
LID v. ROP

Concentration (mg mL-1)
0.625
0.625
1.25
1.25
1.25
2.5
5
10
10
0.625
1.25
1.25
2.5
2.5
5
5
10
10

Mean Difference
79.45
65.33
89.73
42.61
47.12
54.53
58.91
53.16
51.70
10.27
18.30
24.22
35.63
27.94
9.708
10.93
13.56
13.01

P Value
0.0002
0.0014
<0.0001
0.0219
0.0219
0.0111
0.0057
0.0137
0.0137
0.0183
0.0002
<0.0001
<0.0001
<0.0001
0.0410
0.0303
0.0061
0.0061

Table 3.5. Local anesthetics’ statistically significant results of P. aeruginosa planktonic and
biofilm growth.
Bacteria State
Planktonic

Biofilm

Comparison
BUP v. LID
LID v. ROP
BUP v. LID
LID v. ROP
BUP v. LID
BUP v. ROP
LID v. ROP
BUP v. LID
LID v. ROP
BUP v. LID
LID v. ROP

Concentration (mg mL-1)
0.3125
0.3125
0.625
0.625
0.3125
0.3125
0.3125
0.625
0.625
1.25
1.25
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Mean Difference
37.16
25.86
43.97
32.99
31.50
17.38
14.11
18.40
13.43
18.17
14.35

P Value
0.0017
0.0245
0.0002
0.0037
<0.0001
0.0029
0.0082
0.0025
0.0230
0.0028
0.0146

Discussion
The results of this study confirm our hypothesis that certain combinations of LA and
C2DA can reduce both planktonic and biofilm-associated bacterial growth for S. aureus,
P. aeruginosa, and A. baumannii. Overall, C2DA exhibited antimicrobial properties consistent
with previous publications (25). Slight differences in LA structure may explain their varying
efficacies in each study. BUP is an amide with slow onset and prolonged action (20). Razavi et
al. further validated that BUP is typically more effective against Gram-positive strains, including
S. aureus. Previous studies have shown BUP to be the least effective against P. aeruginosa (20,
34). LID is also an amide but with a rapid onset and intermediate duration of action compared to
BUP (20, 35). ROP is very similar in structure to BUP, with differences in length of the alkyl tail
(20, 36). Based on these similarities to BUP, one could hypothesize that similar antimicrobial
activity may be present for ROP. However, in most tested metrics, ROP’s antimicrobial activity
was less robust than BUP (37, 38). This study confirms that the alkyl chain length may play a
role in the mechanism of action, with longer chain lengths interacting with lipophilic parts of the
cell membrane. Studies of phenolipids have indicated that increasing alkyl lengths support more
significant interaction and penetration into lipid bilayers (39, 40). Solubility differences between
LAs may further explain their varying efficacies, as we observed poor solubility of ROP at
neutral pH.
Because LAs mechanism of action against bacteria remains unclear, it is not easy to
pinpoint the reasons for our observed differences in susceptibility between Gram-negative
P. aeruginosa and A. baumannii, which have similar antimicrobial susceptibility (41). LID had
limited efficacy against S. aureus at concentrations below 10 mg mL-1, as seen in previous
studies (42) but was markedly more effective when combined with C2DA. ROP and S. aureus
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demonstrated similar results based on previous studies (37, 42) and was more potent when
combined with C2DA. BUP was more inhibitory in planktonic studies than other LAs and
particularly active against S. aureus; this result confirms previous accounts that BUP possesses
the lowest MIC of these three tested LAs (24, 43). Results reveal that all LAs inhibit planktonic
growth of all bacterial strains at 10 mg mL-1, except for ROP against A. baumannii. The apparent
inactivity of ROP against A. baumannii may have been due to the solubility issues mentioned
earlier, which was one limitation of this study. We chose pure formulations over hydrochloride
salts to avoid confounding effects of varying pH and other excipients included in commercial
anesthetic solutions. Further, non-salt forms may facilitate loading into biomaterial drug delivery
systems more readily, including wound dressings (44, 45), calcium sulfate (46), and polyethylene
(24).
Many antimicrobials have decreased efficacy in inhibiting biofilm formation than
planktonic growth (47), with lower concentrations sometimes driving increased biofilm
formation as an adaptive response (48). This tolerance of biofilm to antimicrobials fits with the
observation that S. aureus biofilm reduction followed a similar dose-response pattern for both
planktonic and biofilm but with higher concentrations required to inhibit biofilm formation by
more than 50%. LAs may interact with surface-attached proteins instrumental in S. aureus
biofilm formation, termed microbial surface components recognizing adhesive matrix molecules
(MSCRAMM), to prevent attachment and thus inhibit biofilm formation (49). The P. aeruginosa
results also reflect biofilm's tolerance and may indicate that the stress of exposure to
antimicrobial LA molecules promotes biofilm formation. Another explanation of P. aeruginosa
biofilm tolerance may be type IV pili and EPS to attach to surfaces, which LAs and C2DA may
not target (50-52).
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In contrast, our results for A. baumannii show that although planktonic growth was not
inhibited and may increase in response to LAs, biofilm inhibition occurred in a dose-dependent
fashion. This high efficacy against biofilm formation may be due to LAs interfering with
chaperone-usher pili used by A. baumannii to attach to abiotic surfaces (53, 54). Biofilm
dispersal may explain the increased planktonic viability and biofilm decrease (55). A study
limitation is that we investigated initial biofilm formation only; future studies may explore the
application of LAs and C2DA to existing biofilms. A further limitation is that only one measure
of bacterial viability was used, which may vary based on metabolic state (ATP production).
Future studies may use additional criteria such as CFU counting, although ATP-based assays
help initial screening studies.
Combining antimicrobials, particularly antibiofilm and antimicrobial molecules, may
work in multiple or divergent ways to increase the efficacy of both (56). C2DA may increase
membrane permeability, which may allow for more antimicrobial molecules to enter the cell
(30). Our additive and synergy findings for planktonic S. aureus but indifference against biofilm
may be due to the limited ability of C2DA to access cell membranes when S. aureus is in a
biofilm instead of a planktonic state. P. aeruginosa produces C2DA, a natural dispersal molecule
that is effective against multiple bacteria and fungi strains (8). The additive responses observed
for P. aeruginosa and A. baumannii may be due to C2DA stimulating dispersal events. C2DA
has an alkyl tail ten carbons long, facilitating interaction with and penetration into lipid bilayers
(39, 57, 58). Both C2DA and BUP may act as penetration enhancers due to their alkyl chain
lengths (59), meaning that their combination could allow for more entry of both inside the
membrane and increased membrane damaging effects. The acidic nature of C2DA may protonate
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the amine groups in LA molecules and increase their solubility (60). However, in vivo studies
must be performed to confirm additive and synergistic activities of C2DA and LAs.
This study indicates the potential success of combining LAs and C2DA as a therapeutic
combination to prevent or treat infection following musculoskeletal trauma. Clinical applications
involving deep tissue damage such as joint replacement surgery, dressings for burn wounds,
compound fracture fixation, or other traumatic injuries may benefit from local delivery of these
therapeutics, alone or in combination. The development of biomaterial delivery systems can
achieve this clinical need for infection prevention and possible treatment. Further studies will
investigate sustained delivery strategies and in vivo efficacy to validate the potential of LAs and
C2DA combination in infection treatment and prevention. In addition to preventing infection,
local delivery of anesthetics may provide additional pain relief for orthopaedic trauma or total
joint procedures, lessen systemic delivery shortcomings, and reduce the need for prescription
opioids, which in turn may mitigate opioid misuse and addiction.
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4. CHAPTER 4
Efficacy of Chitosan-Mannitol Paste Loaded with Bupivacaine for Treatment of a
Rat S. Aureus Infection Model

Introduction
Implant and bone tissue contamination with bacteria poses a dire orthopaedic surgery
complication, leading to bone infections. Biomaterials can, unfortunately, facilitate biofilm
formation by providing a substrate for attachment but are tailorable to treat or inhibit these
infections (1). Osteomyelitis commonly occurs in the long bones of the legs; however, it may
happen in any bone in the body (2). Long bone metaphysis, i.e., tibia and femur, are frequently
involved in long bone osteomyelitis, attributed to the metaphyseal region’s anatomy (2). During
an active osteomyelitis infection, blood flow becomes sluggish and disordered, allowing bacteria
to settle, initiate colonization, and trigger an inflammatory response (2). Multidisciplinary
treatment protocols, including surgical debridement and long-term antimicrobial therapy, are
current strategies for bone infection treatment and lead to additional trauma and costs for patients
(3-5). In adults, the most common organism isolated from osteomyelitis infections is
Staphylococcus aureus (S. aureus) (6) and forms complex infections even without associated
implant material (1).
S. aureus and Staphylococcus epidermidis are two of the most causative bacteria in
osteomyelitis and are known for their ability to form biofilms (2). A biofilm contains a
microbially derived sessile community, with cells attached to a substratum, interface, or each
other. Biofilms can secrete and become embedded within an exopolymeric substance (EPS),
which provides an initial barrier to immune cells and treatment. Additionally, typical biofilm
characterization includes an altered phenotype that alters growth, protein production, and gene
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expression, which all contribute to the ability of bacterial cells to evade clearance (7). These
mechanisms lead to low metabolic levels and reduced cell division that contribute to the capacity
of biofilm-associated bacteria to withstand up to 1000x the minimum inhibitory concentration of
antibiotics (8).
Since 1884, local anesthetics (LAs) have been an instrumental pain management strategy;
more recently, LA use has expanded due to their antimicrobial activities (9). Bacteriostatic,
bactericidal, fungistatic, and fungicidal properties have been exhibited against a broad spectrum
of microorganisms by many LAs with bupivacaine (BUP) and lidocaine (LID) showing
inhibitory effects at clinically relevant concentrations (9). High clinical concentrations of BUP
inhibit the growth of Escherichia coli, S. aureus, S. epidermis, Streptococcus pneumoniae,
S. pyogenes, Enterococcus faecalis, Bacillus cereus, and Candida albicans (10).
Incorporating LAs into antimicrobial systems could be advantageous in decreasing the
prevalence of infection and reducing the need for prescription pain medications. Local anesthetic
delivery provides the highest possible concentration and focuses the treatment at the site where
pain relief is most needed, reducing known systemic delivery issues. Numerous local delivery
systems have been proposed that deliver local anesthetics (11-16). Locally delivering anesthetics
minimizes the risk of adverse side effects by limiting contact or reaction with undesired targets.
LAs, particularly LID, are often added to operative anesthesia solutions to reduce pain on
intravenous injection (9). One study shows that while propofol alone promotes bacterial growth,
combining LID with propofol inhibits growth significantly (17). These studies suggest that the
inclusion of LAs within local delivery systems may effectively prevent or treat an infection.
Local antimicrobial delivery systems are suitable routes for acute and chronic wound infection
treatment, particularly as an adjunct to systemic antimicrobial delivery. Two commonly used
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local delivery systems that administer antibiotics in clinical practice are poly (methyl
methacrylate) (PMMA) and calcium sulfate (CaSO4). PMMA beads loaded with antibiotics
provide a predictable release for several weeks while reducing infection rates in severe open
fractures (18). However, PMMA beads do not biodegrade and require additional surgeries for
removal; they may also potentially deliver sub-inhibitory antibiotic concentrations, which may
encourage incidences of bacteria tolerance or biofilm formation on their surface (18-24). CaSO4
is biodegradable, but has several disadvantages, such as elevated wound drainage, limited
antimicrobial choices and dosing, and a high initial, not sustained, burst release of loaded
antimicrobial at the wound site (25-28).
Chitosan is a biocompatible, biodegradable, natural polymer that may serve as a
promising alternative to existing drug delivery systems. Chitosan has been developed and studied
in various formulations, including sponges, membranes, films, and pastes (29). Utilizing chitosan
in paste form may be particularly useful for drug delivery to complex musculoskeletal injuries,
as pastes can penetrate and conform to irregular tissue geometries. Previous studies have
confirmed the efficacy of chitosan pastes in delivering antibiotics to wound beds; more recently,
as an additional measure to increase the susceptibility of dormant bacterial cells to antibiotics,
the sugar alcohol, mannitol, has been added to the chitosan paste (30-32). However, a limitation
of previous paste formulations is that they do not allow for the loading of hydrophobic molecules
readily. Previous work with acylated chitosan membranes has shown that they can load
hydrophobic molecules through an ethanol evaporation process that also provides
extended-release (33). In this study, we sought to determine if the addition of BUP to previously
studied chitosan-mannitol pastes with an acylated component would increase the efficacy.
Additionally, we sought to evaluate the antimicrobial activity of this local drug delivery system
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through in vitro elution studies and a preliminary in vivo contaminated composite tissue defect
model.
Materials and Methods
Fabrication
Chitopharm S chitosan powder (Chitinor AS, Tromsø, Norway; 82.46 ± 1.679 DDA;
250.6 kDa average molecular weight) was dissolved at 1% (w/v) with 1% (w/v) polyethylene
glycol (PEG) (Sigma Aldrich, St. Louis, MO, USA; 8,000 g mol-1 average MW) in 0.85% (v/v)
acetic acid in deionized water solution; mannitol (Bulksupplements.com) was dissolved at 2%
(w/v) in the previously described solution to form the chitosan-mannitol paste blend. The
solutions were cast in 25 mL aluminum dishes and frozen overnight at -80 °C, then lyophilized
in a benchtop freeze dryer (LabConco, Kansas City, MO, USA) to create acidic dehydrated
sponges. Some sponges without mannitol were saved for use as controls during elution studies.
Acidic control sponges were neutralized using 1 M sodium hydroxide (NaOH). The remaining
chitosan-mannitol sponges were ground into fine powders (paste) and stored in a desiccator until
sterilization with ethylene oxide gas with appropriate degassing occurring at the sterilization
facility (34, 35). Hexanoic anhydride acylated the paste with a method similar to Wu et al. In
brief, pyridine then hexanoic anhydride were added to the chitosan paste (10 mg mL-1) at a 1:1
ratio and reacted under constant stirring for 1.5 hours. Once the reaction time was complete, the
paste was vacuum filtered and washed five times: 1) 10% acetone (30 min), 2) 70% absolute
ethanol (30 min), 3 - 5) deionized (DI) water (30 min each), and finally rinsed with acetone. The
paste was removed from the filtration system and stored until further use.
To incorporate BUP into the acylated paste and achieve sterilization, BUP was
solubilized in absolute ethanol (14 mg mL-1), then 6 mL was added to 500 mg of acylated paste
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in a plugged syringe. The ethanol was evaporated overnight (37 °C), leaving the BUP combined
with the acylated paste in a dry state. Neutralized control sponges were diametrically sectioned
(6 mm), placed into syringes (~500 mg), and loaded with BUP in the same manner as the
acylated paste.
The BUP-loaded acylated paste was mixed with unmodified paste. First, 500 mg of unmodified
paste was hydrated with 6 mL PBS using two 10 mL syringes and a Luer lock connector
(Qosina, Ronkonkoma, NY). The PBS and unmodified paste were mixed several times until a
uniform mixture formed with minimal resistance observed when transferring mixture between
syringes. The bupivacaine-loaded acylated paste (500 mg) was then mixed with the unmodified
hydrated paste through another coupled syringe. Like the hydration process, the mixing process
was continued until a visible uniform mixture (BAHP) was obtained.
Elution
Sectioned sponges (n = 4) or 150 mL BAHP paste (n = 4) were placed in 8 mm pore size
Costar® inserts. Inserts were placed in Costar Transwell ® plates and immersed in 1 mL PBS.
Plates were covered with parafilm to minimize potential eluent evaporation. Next, plates were
placed in a MidSci™ LabDoctor™ Mini Incubator Shaker at 37 °C and 30 rpm. Daily sampling
occurred over seven days with complete PBS refreshing at the time of sampling. Eluates were
frozen until further analysis. At the time of analysis, frozen eluates were thawed, vortexed, and
centrifuged before being transferred (200 mL) to a 96-well plate for BUP concentration
determination using a ThermoScientific Dionex Ultimate 3000 Series high-performance liquid
chromatography (HPLC) system. BUP was detected using UV with 1.9 µg mL-1 limit of
detection using a 5 µL injection volume at l= 200 with a 2 mL min-1 flow rate, 5.3 min retention
time using a BDS Hypersil GOLD reversed-phase C18 column (250 x 4.6 mm, 5 µm particle
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size, 175 Å pore size) and an isocratic mobile phase. Mobile phase was 50% buffer (0.68%
potassium dihydrogen phosphate, 0.05% triethylamine to 6.5 pH using orthophosphoric acid) and
50 % acetonitrile.
Rat Traumatic Wound Model
The Institutional Animal Care and Use Committee (IACUC) of Mississippi State
University approved the animal research performed within this work under the protocol 20-153.
Charles River Sprague Dawley 13-week old female rats were anesthetized with isoflurane at an
initial concentration of 5% at 3 L min-1 O2 and sustained at 1 - 2% at 1 L min-1 O2. Following
sterile left hindlimb preparation with alcohol, chlorhexidine scrubs, and fur removal, the skin
was incised using an anterior approach. An incision was made from mid-diaphysis to the patella
along the lower half of the femur. Muscle tissue was separated at the muscle bundle division by
blunt dissection along the along the anterolateral side of the femur. Rat post-operative pain relief
occurred by administering buprenorphine (1.0 - 1.2 mg kg-1 BW, ZooPharm). A pneumatic drill
(Conmed Hall) and a #65 drill bit (McMaster-Carr) were used to create a 1.2 mm (Æ) bicortical
defect in the mid-diaphysis. Sterile orthopaedic screws (Antrin Miniature Specialties, #00-90)
were placed in 200 mL of bacterial suspension (~1x108 CFU) of ATCC 6538-GFP for an
average of 5.25 min, range 4 - 6 min, to mimic orthopaedic screw S. aureus contamination in a
traumatic wound or to develop osteomyelitis in vivo. The screw was subsequently dried in a
96-well plate for a 2 min average to a maximum of 5 min. Determining the contaminated screws’
bacterial load was achieved by placing screws in PBS (1 mL), vigorously vortexing the screws to
detach bacteria from screws, and then serially diluting the eluents for bacterial counting on BHI
agar plates. Bacterial load was confirmed by vortexing and dilution plating of representative
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samples inoculated at the same time to determine CFU. The superficial fascia lata and skin were
closed with sutures to complete the in vivo procedure.
After a 7-day infection period, the area was accessed along the original incision line. The
infected screw was removed and placed in 1 mL PBS for bacterial counting. The infection site
was debrided, and all accessible pus was removed. The remaining defect area was either resealed
without treatment, treated with unloaded chitosan paste (150 µL), or BUP-loaded chitosan paste
(150 µL). Injections of treatments were done using a sterile 18-gauge needle placed onto a 1 mL
syringe loaded with one of the two treatments.
IVIS Imaging
Two animals were chosen from each group based on temperament and reactions to
isoflurane for longitudinal x-ray and fluorescence imaging 1, 7, 14, 21, and 28 days after
treatment using the IVIS Lumina XRMS II system. Fluorescent and photographs were selected
for one overlay image then the x-ray was captured immediately after. Fluorescent was set to auto
exposure time, small binning, F stop-1 of 1, excitation filter of 480 nm, and an emission filter of
520 nm. The photograph was set to auto exposure time, small binning, and F stop-1 of 8. X-ray
was sent to auto exposure time, high resolution binning, and F stop-1 of 2. The animals were
induced and maintained on isoflurane at 2% with 1 L min-1 O2. The lower threshold for
fluorescence was increased 1/2 an order of magnitude of radiant efficiency to reduce the overlap
effect of excitation and emission wavelengths.
Retrieval
On day 28 post-treatment, animals were euthanized via CO2 inhalation. The animals had
their dermis removed caudal of the scapula to their mid-tibia, and sterile instruments
disarticulated the femur and adjacent soft tissues for further evaluation. For bacterial counting,
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bone samples (n = 20) were initially minced with sterile bone rongeurs and further processed
using a homogenizer (Cole-Parmer, LabGEN7, 30 s at setting 2 - 3, 30 s at setting 9 - 10). Soft
tissue samples (n = 20) were minced using sterile scissors, then homogenized (30 s at setting
2 - 3, 30 s at setting 7 - 8). After initial processing, homogenates were vortexed (2000 RPM,
1 min), diluted as required, spread onto BHI agar plates, and incubated for 24 hours at 37 °C for
enumeration, with a 25 - 250 colonies detection limit.
Histology
Following the sacrifice of animals, one animal in each group was selected for histological
analysis. Bone and surrounding tissue were harvested and preserved in a 10% neutral formalin
solution. Tissue samples were decalciﬁed with formic acid, embedded in parafﬁn, sectioned into
5 µm slices, and stained with hematoxylin and eosin (H & E).
Statistical analysis
Statistical analysis was performed using SigmaPlot and GraphPad Prism 7.2 software
(GraphPad Software Incorporation, La Jolla, CA, USA). Data was assessed first by performing a
Shapiro-Wilk normality test, followed by a Brown-Forsythe equal variance test. If both passed,
data were further analyzed with a one-way analysis of variance (ANOVA) followed by
Holm-Sidak’s post-hoc analysis to detect significance between experimental groups (α = 0.05). If
normality and equal variance were not passed, data were analyzed using Kruskal-Wallis
ANOVA on ranks, followed by Tukey post-hoc test.
Results
Elution
BUP eluted from chitosan paste and control sponge groups with a pseudo-zero-order
release profile, with the paste groups showing a slightly higher release on day one. Cumulative

70

release of BUP saw paste release at a marginally lower level compared to the sponge control.
BUP continued to release at detectable levels for the duration of the 7-day study (Figure 4.1).
The cumulative BUP release shows the chitosan sponge releasing at a higher rate with greater
cumulative volume (Figure 4.2).
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Figure . Mean ± standard deviation of daily average bupivacaine eluate concentration
when eluted from chitosan sponge and modified paste (n = 4).
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Figure 4.1. Mean ± standard deviation of cumulative bupivacaine eluate release when
eluted from chitosan sponge and modified paste (n = 4).
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IVIS
Longitudinal IVIS images show reduced S. aureus growth in animals treated with
BUP-loaded paste at all time points, though bacterial growth was not eliminated. Animals treated
with unloaded paste showed sufficient bacterial growth at day one and week one posttreatment
but subsequent reduction by week 3 (Figure 4.3).

Figure 4.2. IVIS images of S. aureus over the duration of the study.

CFU Counts
CFU counts for retrieved soft tissue were markedly lower than those for bone
(Figures 4.4 & 4.5). Soft tissue bacterial counts showed similar results for untreated animals and
animals treated with unloaded paste, with decreased CFUs for BUP-loaded paste and less
variability. Overall, there were higher CFU counts from retrieved bone were higher. The highest
bacterial burden is seen with untreated animals, followed by those treated with unloaded paste
and the lowest bacterial growth for animals treated with BUP-loaded paste; again, the BUP
treated animals had minor CFU count variability.
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Figure 4.3. S. aureus’ CFU gram-1 of soft tissue harvested from rats following treatment with pastes
(n = 3).
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Figure 4.4. S. aureus’ CFU gram-1 of bone harvested from rats following treatment with pastes
(n = 3).
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Histology
Representative histological images of treated and control animals four weeks after
material implantation show mild inflammation for animals treated with unloaded paste and
moderate inflammation for animals treated with BUP-loaded paste (Figure 4.5). There was no
visible chitosan paste remaining in wounds.

Figure 4.5. Photomicrographs (4x magnification) showing sections of soft tissue and
bone from retrievals.

Discussion
This model evaluated the efficacy of chitosan-mannitol paste loaded with BUP and
2-decenoic acid to prevent internal S. aureus osteomyelitis and contiguous soft tissue infection in
a rat model. The formulation of acylated particles within an injectable paste offers advantages
over other delivery vehicles in that it can be more readily applied to complex geometries of
tissue injuries. Overall, the results demonstrated an effect of the proposed treatments in reducing
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viable S. aureus CFUs in the bone and the surrounding soft tissue. However, rebounding
infection indicates that doses of antimicrobial were insufficient for biofilm eradication.
BUP-loaded paste produced the most significant reduction of S. aureus viable units in the bone,
consistent with previous studies (36, 37). Modification of paste components by acylation,
reported for the first time in this study, may serve as a basis for subsequent refinement of
material fabrication and loading strategies for future studies.
The non-acylated paste is capable of being loaded with hydrophilic therapeutics, which
results in first-order release kinetics. Multiple previous studies involving non-acylated paste
could be passively loaded and subsequently release hydrophilic therapeutics at levels above
investigated bacteria MICs (38-41). Previously studied paste systems have exhibited first-order
release kinetics and release most if not all loaded therapeutics within 72 hours. During Beretta et
al. studies, hydrophilic therapeutics were released almost entirely from pastes within 24 hours
(39). Alexander et al. developed a thermogelling chitosan paste that released vancomycin for
detectable levels through five days, but at deficient levels after day two. When including
mannitol into the chitosan paste, Pace et al. determined elution of hydrophilic therapeutics
extended through seven days and had a lower initial burst release than non-mannitol paste (30).
The acylated paste, in contrast, provides opportunities to load hydrophobic therapeutics, which
has previously been challenging to achieve. BUP-loaded pastes can realize pseudo-zero-order
release of high concentrations of antimicrobials locally, although released levels may not totally
eradicate biofilm. Elution from the acylated paste shows an ability to be sustained at a constant
level for up to seven days, resulting from the hydrophobic nature of the modified paste’s surface.
Theoretical bupivacaine loading calculations indicate that approximately 6% of loaded
bupivacaine was released from BAHP during the 7-day study, providing support for evaluating
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bupivacaine release from BAHP over a longer time frame. Future studies will perform
techniques to determine the exact amount of bupivacaine loaded into the BAHP. Zero-order
extended-release of simvastatin, a hydrophobic therapeutic, has been reported from acylated
nanofibrous membranes (33). The acyl modification of the material may enable the loading of
other hydrophobic antimicrobials, such as the biofilm-active rifampin and ciprofloxacin.
Previous studies of rifampin and ciprofloxacin loaded within sponges demonstrated challenges in
solubilizing and releasing these for an extended time (42). When attempting to inhibit
bacteria-derived infections, a sustained release is often one of the primary objectives and may
provide an adjunct therapy to systemic delivery. An advantage of using bupivacaine as the
antimicrobial component is that pain reduction may occur over an extended period of delivery
(43). However, we did not directly measure pain outcomes in this study.
Biofilm-associated infections depend on their ability to remain in a state that is counter to
their planktonic state. CFU bone analyses show that the proposed therapeutics do not eliminate
the presence of bacteria. However, the longitudinal IVIS images indicate that initial bioburden
may be reduced in groups loaded with antimicrobials. Failure to eliminate bacteria could be a
result of insufficient loading. Maximizing therapeutic loading is critical to having a therapeutic
system that can inhibit or eradicate a bacteria-derived infection, especially when treating
biofilms, which can withstand high antimicrobial concentrations (44). In addition to improper
loading, lack of adhesion may contribute to the pastes’ limited residency time in the defects and
surrounding areas and explain persisting infection. Although we did not directly measure
degradation in this study, previous studies demonstrate that unmodified mannitol-based pastes
degrade approximately 72% of their mass in vitro over 14 days (30). The majority of the paste is
injected directly into the bone defect in this model. Still, it may have enhanced diffusion through
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soft tissue, explaining the markedly lower CFU counts in the soft tissue than in the bone.
S. aureus is known to invade the osteocanalicular network of bone, which also poses challenges
to adequate delivery (45). The defect size required specific syringe gauge sizes for therapeutic
application, which may have resulted in inconsistent delivery. The available space, which
influenced the sight field and availability of components that can load therapeutics, impaired the
treatment placement. Therapeutic paste composition, which affects injectability, may be refined
in future experiments to ease mixing and increase the acylated component for increased loading.
These issues would be less impactful in larger animal models, improving all stated limitations
regarding the proper therapeutic application, placement, and residency time. Increasing the ratio
of the less degradable acylated component may alco increase residency time to further extend
release and efficacy.
Treatment of existing biofilm infection is particularly challenging, although the results of
this study may indicate a role for this biomaterial paste in infection prevention. Future studies
may evaluate these systems delivered at the time of initial contamination. Closely related to
residence time is the placement of the treatment into the defect area. The chance for complete
clearance significantly reduces if the therapy is inaccurately loaded. When the treatment is
applied, the paste must be in the defect area, providing the best chance for effective antimicrobial
activity. Not having the paste appropriately in the area requiring treatment affects residency time
and antimicrobial activity since both require contact with the bacteria.
Conclusions
Acylated chitosan-based biomaterials provided a foundation to load and deliver
hydrophobic compounds otherwise not possible without additional considerations. The
therapeutic system achieved the study objective of reducing an S. aureus-based infection;

77

however, there remains room for improvement. While engineered for hydrophobic compounds,
the system could benefit from slight modifications allowing for incorporation of hydrophilic
antibiotics. Future studies should evaluate the antimicrobial efficacy of chitosan-based
biomaterials directly acylated with known antimicrobial therapeutics. While the results are
promising, future studies should assess bupivacaine combined with other proven antimicrobials,
e.g., other local anesthetics, 2-decenoic analogs, antibiotics, and their combinations. Additional
upcoming studies should test acylated biomaterial in a polymicrobial infection model.
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5. CHAPTER 5
Conclusions
The results presented in this dissertation indicate that chitosan-based biomaterials are
modifiable with fatty acid chlorides. The custom chloride synthesis route increases previously
inaccessible compounds to modify chitosan-based biomaterials with the acylation process.
Acylated chitosan-based biomaterials are cytocompatible with properties that inhibit infection
and biofilm. Based on previous studies, the pain mitigation effects of LAs are assumed to be
consistent with the in vivo and in vitro functionality observed with the modified chitosan-based
biomaterials.
Chapter 2 demonstrated the ability to synthesize fatty acid chlorides from compounds that
are themselves synthesized or not available commercially. Unmodified chitosan-based
biomaterial material characteristics, i.e., fiber structure and size, do not significantly change after
modification with fatty acid chlorides. Cytocompatibility is not adversely affected and may
increase after the chitosan-based biomaterials surfaces are modified. Chitosan-based
biomaterials’ surface modification increases the baseline antimicrobial properties compared to
their unmodified counterparts. Additionally, modifying chitosan-based biomaterials with fatty
acid chlorides allows elution profiles to be customized.
The antimicrobial studies conducted in Chapter 3 confirm previous studies concerning
the antimicrobial ability of local anesthetics. It is critical to note that the work in Chapter 3
determined the local anesthetics’ true baseline antimicrobial capabilities since the investigated
compounds were not acid-formulated, as seen in many previous works. Nonacid formulated local
anesthetics are more challenging to work with and may not be feasible for point-of-care loading;
however, they provide an excellent basis for prefabricated treatment options.
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The results in Chapter 4 support the use of modified chitosan-based biomaterials in local
delivery infection prevention systems. Modified chitosan-based biomaterials can be loaded with
multiple antimicrobial therapeutics and elute those loaded therapeutics at levels that assist in
controlling an infection. Moreover, the results obtained during this in vivo infection model were
for an established infection. Positive results from this chapter are more promising since the
engineering of the chitosan-based biomaterials used during this investigation was for an infection
inhibition role. Engineered technological enhancements are possible to make the modified
chitosan-based biomaterials better suited to fight established infections. Furthermore, this study
produced the results without potentially maximizing clinically relevant therapeutic loading.
These factors, among others, offer promise for the future of the investigated therapeutic
combination used with the modified chitosan-based biomaterial or another comparable modified
chitosan-based biomaterial.
Local delivery systems that include fatty acid chloride modified chitosan-based
biomaterials possess the ability to load and deliver hydrophobic therapeutics. Many local
delivery systems are extremely limited in this manner. Local delivery systems with fatty acid
acyl-modified biomaterials demonstrate a reduced initial burst release and subsequently perform
with a pseudo-zero-order release profile over more than seven days. This study’s elution release
profile is an improvement over other local delivery systems that, on average, release loaded
therapeutics with a first-order release profile and within the first week. Local delivery systems
that include modified biomaterials do not degrade as fast as other local delivery systems. This
improvement gives the local delivery system more residency time in or around to deliver any
loaded therapeutic, possibly extending antimicrobial activity. There are numerous potential
clinical implications beyond infection prevention and treatment for acyl-modified local delivery
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systems. Expanded potential clinical applications for these include delivering hydrophobic drugs,
i.e., chemotherapeutics and tissue and bone regeneration methods.
6. CHAPTER 6
Recommendations for Future Work
Additional research evaluations on acylated chitosan-based biomaterials should seek to
understand better their properties and functionality for local antimicrobial therapeutic delivery
and infection prevention. These properties include determining the degree of substitution and
utilizing nuclear magnetic resonance to gain more knowledge of molecular structure changes if
they exist. Functionality investigations should evaluate the acyl-modified chitosan-based
biomaterials’ antimicrobial efficacy without any additionally loaded antimicrobials. Further in
vitro elution evaluations and activity research with other hydrophobic antimicrobials, such as
ciprofloxacin or rifampin, may increase potential clinical applications of acylated chitosan-based
biomaterials. Auxiliary in vitro elution evaluations should incorporate certain well-known
antibiotics, e.g., vancomycin or amikacin, to determine functionality with standard clinical
treatment options. Therapeutic loading capacities require testing to maximize the infection
prevention time-frame and elution properties. Additionally, if the therapeutics include local
anesthetics, future studies should maximize the loading levels to benefit pain relief and
antimicrobial efficacy. Ongoing studies should evaluate local anesthetics in various
combinations against a broad spectrum of microorganisms. Antimicrobial efficacy for the tested
local anesthetics varied depending on strain and phenotype, i.e., planktonic versus biofilm.
Combining local anesthetics could provide inhibition against polymicrobial infections.
The degradation properties of acylated chitosan-based biomaterials require further
assessment. Hydrophilic chitosan-based biomaterials have demonstrated promising in vitro and
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in vivo degradability; however, acylated chitosan-based biomaterials are hydrophobic. The
degradation evaluation should correlate with expected residency time within the body, e.g.,
30 – 180 days, or at the wound site, which varies depending on the application, i.e., wound
dressing or treatment component, and wound severity. Future in vivo models of infection
prevention should provide a more definitive biofilm and infection inhibition assessment. Finally,
upcoming studies should evaluate acylated chitosan-based biomaterials in a large in vivo animal
model with clinically representative traumatic musculoskeletal wounds.
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8. Appendices
Appendix A.
Animal Use Protocol Approvals
1. Mississippi State University Institutional Animal Care and Use Committee Protocol
Approval Letter
Protocol 20-153 Approval: Efficacy of Chitosan-Mannitol Paste Loaded with
Bupivacaine for Treatment of a Rat S. Aureus Infection Model
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June 22, 2020
Lauren Priddy
Ag & Bio Engineering
Re: Protocol # IACUC-20-153
Dear Lauren:
The Mississippi State Institutional Animal Care and Use Committee (IACUC) has completed it's review of your protocol
titled Biomaterial delivery vehicles for antimicrobial treatment of osteomyelitis. In light of federal policies on the care and
use of animals in research and requirements established specifically for the Institute, the committee has chosen to grant
approval of this protocol on June 22, 2020. The expiration date for this project will be June 21, 2023 and the approval
number is IACUC-20-153.
If you would like to involve additional members in this protocol or change aspects of the protocol in the future, please
submit a Protocol Amendment Form for review.
Concurrent with this approval, please be advised the MSU-IACUC holds the principal investigator(s) named in this protocol
responsible in ensuring that each procedure described in the protocol will be followed exactly (unless amended and such
amendment is approved by the IACUC before implementation).
If the animal care and use aspects of this study change, approval of a new protocol or of an amendment is necessary. The
project must be reviewed by the IACUC annually with the number of animals used during the year reported to the IACUC
on the annual update form. When the project is complete, please notify the IACUC Administrator, Trina Smith, at 325-0994.
The committee appreciates your cooperation and wish you continued good luck in your research endeavors.
Sincerely,
Brian Rude
Chair, IACUC
brude@ads.msstate.edu
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